The bone anabolic carotenoid β-cryptoxanthin enhances transforming growth factor-β1-induced SMAD activation in MC3T3 preosteoblasts

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 671-675

  Yamaguchi, Masayoshi ^a   Weitzmann, M Neale ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

cryptoxanthin; Bone formation; Osteoblast; Osteoporosis; SMAD; Transforming growth factor 1

Indexed keywords

BETA CRYPTOXANTHIN; BONE MORPHOGENETIC PROTEIN 2; LUCIFERASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; IN VITRO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSIENT TRANSFECTION;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CAROTENOIDS; CELL DIFFERENTIATION; MAP KINASE KINASE KINASES; MICE; OSTEOBLASTS; PROTEIN KINASE INHIBITORS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; XANTHOPHYLLS;

EID: 70350761408     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000278     Document Type: Article

References (31)

1. Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186-1194, 2006.
2. Yamaguchi M: Isoflavone and bone metabolism: Its cellular mechanism and preventive role in bone loss. J Health Sci 48: 209-222, 2002.
3. Yamaguchi M: Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. Yakugaku Zasshi 126: 1117-1137, 2006.
4. Yamaguchi M and Uchiyama S: Effect of carotenoid on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro: The unique anabolic effect of β-cryptoxanthin. Biol Pharm Bull 26: 1188-1191, 2003.
5. Yamaguchi M and Uchiyama S: β-Cryptoxanthin stimulates bone formation and inhibits bone resorption in tissue culture in vitro. Mol Cell Biochem 258: 137-144, 2004.
6. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates cell proliferation and transcriptional activity in osteoblastic MC3T3-E1 cells. Int J Mol Med 15: 675-681, 2005.
7. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. J Cell Biochem 95: 1224-1234, 2005.
8. Uchiyama S and Yamaguchi M: Inhibitory effect of β-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol 67: 1297-1305, 2004.
9. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates apoptotic cell death and suppresses cell function in osteoclastic cells: Change in their related gene expression. J Cell Biochem 98: 1185-1195, 2006.
10. Uchiyama S, Sumida T and Yamaguchi M: Oral administration of β-cryptoxanthin induces anabolic effects on bone components in the femoral tissues of rats in vivo. Biol Pharm Bull 27: 232-235, 2004.
11. Uchiyama S and Yamaguchi M: Oral administration of β-cryptoxanthin prevents bone loss in streptozotocin-diabetic rats in vivo. Biol Pharm Bull 28: 1766-1769, 2005.
12. Uchiyama S and Yamaguchi M: Oral administration of β-cryptoxanthin prevents bone loss in ovariectomized rats. Int J Mol Med 17: 15-20, 2006.
13. Yamaguchi M, Igarashi A, Uchiyama S, Sugawara K, Sumida T, Morita S, Ogawa H, Nishitani M and Kajimoto Y: Effect of β-cryptoxanthin on circulating bone metabolic markers: Intake of juice (Citrus unshiu) supplemented with β-cryptoxanthin has an effect in menopausal women. J Health Sci 52: 758-768, 2006.
14. Wang Y, Hodge AM, Wluka AE, English DR, Giles GG, O'Sullivan R, Forbes A and Cicuttini FM: Effect of antioxidants on knee cartilage and bone in healthy, middle-aged subjects: a cross-sectional study. Arthritis Res Ther 9: R66, 2007.
15. Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Ando F and Yano M: Bone mineral density in post-menopausal female subjects is associated with serum antioxidant carotenoids. Osteoporos Int 19: 211-219-720, 2008.
16. Granado-Lorencio F, Olmedilla-Alonso B, Herrero-Barbudo C, Blanco-Navarro I and Perez-Sacristan B: Seasonal variation of serum alpha- and beta-cryptoxanthin and 25-OH-vitamin D(3) in women with osteoporosis. Osteoporos Int 19: 717-720, 2008.
17. Yamaguchi M: β-Cryptoxanthin and bone metabolism: The preventive role in osteoporosis. J Health Sci 54: 356-369, 2008.
18. Centrella M, McCarthy TL and Canalis E: Receptors for insulin-like growth factor-I and -II in osteoblast-enriched cultures from fetal rat bone. Endocrinology 126: 39-44, 1990.
19. Palcy S, Bolivar I and Goltzman D: Role of activator protein 1 transcriptional activity in the regulation of gene expression by transforming growth factor β1 and bone morphogenic protein 2 in ROS 17/2.8 osteoblast-like cells. J Bone Miner Res 15: 2352-2361, 2000.
20. Li Y, Li A, Strait K, Zhang H, Nanes MS and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic SMAD activation, through NF-kappaB. J Bone Miner Res 22: 646-655, 2007.
21. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H and Rosier RN: SMAD7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res 312: 40-50, 2006.
22. Yamaguchi M and Weitzmann MN: The bone anabolic carotenoids β-hydroxycinnamic acid and β-cryptoxanthin antagonize NF-?B activation in MC3T3 preosteoblasts. Mol Med Rep 2: 641-644, 2009.
23. Janssens K, Dijke PT, Janssens S and Hul WV: Transforming growth factor-β1 to the bone. Endocrine Rev 26: 743-774, 2005.
24. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH and Franceschi RT: Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14: 893-903, 1999.
25. Fredderick JP, Liberati NT, Waddell DS, Shi Y and Wang XF: Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of SMAD3 to a novel repressive SMAD binding element. Mol Cell Biol 24: 2546-2559, 2004.
26. Li B: Bone morphogenetic protein-SMAD pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets 8: 208-219, 2008.
27. Lee KH and Kim JR: Reactive oxygen species the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocytes growth factor. Exp Mol Med 41: 180-188, 2009.
28. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S and Kishimoto T: Targeted disruption of Cbfa1 results in a comple lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764, 1997.
29. Lian JB, Stein GS, Canalis E, Roky PG and Boskey AL: Bone formation: Osteoblast lineage cells, growth factor, matrix protein, and the mineralization process. In: Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism. Favus MJ (ed). (4th edition). Lippincott Williams & Wilkins Press, New York, pp14-29, 1999.
30. Majeska RJ and Wuthier RE: Studies on matrix vesicles isolated from chick epiphyseal cartilage. Association of pyrophosphatase and ATPase activities with alkaline phosphatase. Biochim Biophys Acta 391: 51-60, 1975.
31. Park CK, Ishimi Y, Ohmura M, Yamaguchi M and Ikegami S: Vitamin A and carotenoid stimulate differentiation of mouse osteoblastic cells. J Nutr Sci Vitaminol 43: 281-296, 1997.